Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MC5R | P33032 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE8B | O95263 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27887715 | 1.00 | PARP1 (0.51) | PARP1EPHX1APAF1IDEHPGD | |
| SCHEMBL31211834 | 0.91 | PARP1 (0.49) | PARP1ATMSMN1; SMN2MC4RMC5R | |
| SCHEMBL31211850 | 0.88 | PARP1 (0.51) | PARP1SMN1; SMN2HSD17B10 | |
| SCHEMBL1990452 | 0.81 | PARP1 (0.54) | PARP1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL337351 | 0.81 | PARP1 (0.54) | PARP1ATMSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL1994122 | 0.81 | PARP1 (0.54) | PARP1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL336577 | 0.81 | PARP1 (0.54) | PARP1ATMSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL1990451 | 0.81 | PARP1 (0.54) | PARP1SMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL336578 | 0.81 | PARP1 (0.54) | PARP1ATMSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL24543368 | 0.80 | PARP1 (0.53) | PARP1SMN1; SMN2HSD17B10PDE8B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| EP-1989188-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-07-22 | — | — | EP | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| EP-2562168-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2014-04-16 | — | — | EP | disclosed |
| US-20140038945-A1 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2014-02-06 | — | — | US | disclosed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| US-8501745-B2 | Piperazine PDE4 inhibitors and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-08-06 | — | — | US | disclosed |
| EP-2562168-A1 | Therapeutic piperazines as PDE4 inhibitors | Helicon Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8338405-B2 | Therapeutic piperazines | DART NEUROSCIENCE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
| US-20110065689-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
| US-20110065688-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE LLC | 2011-03-17 | — | — | US | disclosed |
| US-7829713-B2 | Therapeutic piperazines | HELICON THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| CN-101490017-A | Therapeutic piperazines as PDE4 inhibitors | HELICON THERAPEUTICS INC (US) | 2009-07-22 | — | — | CN | disclosed |
| EP-1989188-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100852-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203124-A1 | Therapeutic Piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | PARP1 748/4885EPHX1 899/4885APAF1 1575/4885 |
| US-20070203124-A1 | Therapeutic Piperazines | PDE4A, PDE4B, PDE12 | PARP1 1492/4885EPHX1 602/4885APAF1 1866/4885 |
| US-20110065688-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE12 | PARP1 1492/4885EPHX1 602/4885APAF1 1866/4885 |
| US-20110065689-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE12 | PARP1 1492/4885EPHX1 602/4885APAF1 1866/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | PARP1 748/4885EPHX1 899/4885APAF1 1575/4885 |
| US-20140038945-A1 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF | PDE4A, PDE12, PDE4B | PARP1 915/4885EPHX1 313/4885APAF1 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.